US National Children's Hospital

New Treatment For Uroepithelial Carcinoma Receives Fda Fast Track Designation With Encouraging Initial Results

New Drug For IDH1 Mutation/Relapsed/Refractory Acute Myeloid Leukaemia With Good Complete Remission Rates And Manageable Toxicity

New York Presbyterian University Hospital of Columbia and Cornell

Heidelberg University Hospital

Genetic Modification Of Immune Cells To Make Them Tireless, Cold-Blooded "Cancer Cell Killers"!